Please complete Pre-test

Chapter 1 of 3

 

 

Release Date: December 15, 2020
Expiration Date: December 15, 2021

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

With many treatment options now available, it can be challenging to stay up-to-date with the latest data emerging from clinical trials. In this activity, our expert faculty weave data reported this year from EHA and ASCO into real-world patient presentations. Please join them as they present four different case scenarios discussing evidence-based treatment options selected and the rationale for their decisions. In addition, they provide insight on the newly approved oral hypomethylating agent, CC-486 (azacitidine tablets), as a maintenance treatment for adult patients with acute myeloid leukemia (AML) who achieved a first complete remission (CR) or CR with incomplete blood count recovery (CRi) after intensive induction chemotherapy and who are unable to complete intensive curative therapy, such as hematopoietic stem cell transplant (HSCT).

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize clinical data supporting advances in novel treatment approaches and best practices for use of available treatments
  • Demonstrate the ability to evaluate, integrate, and apply appropriate information from various sources of clinical data as it relates to emerging treatments and practice standards in AML

Agenda

Chapter 1: Case 1 – Naval Daver, MD - Chair

Chapter 2: Case 2 & 3 – Courtney D. DiNardo, MD, MSCE

Chapter 3: Case 4 & Summary – Naval Daver, MD

Instructions for Participation and Credit

This activity is eligible for credit through December 15, 2021. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Naval Daver, MD
Associate Professor
Department of Leukemia 
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Naval Daver received his medical degree from Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine in Houston, Texas. He is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.

A clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myelofibrosis, Dr. Daver is the co/principal investigator for more than 25 ongoing clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing immune checkpoint- and vaccine-based approaches in AML, myelodysplastic syndromes (MDS), and myelofibrosis, and is conducting a number of these trials. Dr. Daver has published more than 100 peer-reviewed manuscripts. He has also authored numerous abstracts at national and international conferences.

Courtney D. DiNardo, MD, MSCE 
Associate Professor of Medicine 
Department of Leukemia 
Division of Cancer Medicine 
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Courtney DiNardo received her medical degree from the University of Michigan, Ann Arbor. She completed her internal medicine internship and residency, followed by a hematology/oncology fellowship at the University of Pennsylvania. Dr. DiNardo is currently Associate Professor of Medicine in the Department of Leukemia, Division of Cancer Medicine, and Institutional Review Board Vice Chair at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr. DiNardo’s clinical research focuses on prognostication and personalized therapeutics in myeloid malignancies. She is primary investigator of multiple novel IDH1/IDH2-targeted therapeutic agents currently in clinical trials and is also involved in the clinical development of venetoclax in combination with hypomethylating agent therapy for the treatment of newly diagnosed elderly AML. Her clinical and research focus on hereditary cancer predisposition syndromes led to development of the MD Anderson Hereditary Hematologic Malignancy Clinic, which provides clinical and research-based evaluation of underlying cancer predispositions and hereditary cancer syndromes in leukemia patients.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com.

Provided by MediCom Worldwide, Inc.

This activity is supported by educational grants from Bristol Myers Squibb, Helsinn, Genentech, and Jazz Pharmaceuticals.



©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-20-043-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 20-043-131

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Naval Daver has received honoraria related to formal advisory activities and as a consultant from AbbVie Inc., Agios, Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Celgene Corporation – A Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., ImmunoGen, Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Karyopharm Therapeutics, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., and Sunesis. He has received grant support related to research activities from AbbVie, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Inc., GlycoMimetics, Inc., ImmunoGen, Incyte, Karyopharm, Nohla Therapeutics, Novartis, Pfizer, SERVIER, and Sunesis.

Dr. Courtney DiNardo has received honoraria as a consultant from AbbVie Inc., Agios, Celgene Corporation - A Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Immune-Onc Therapeutics, Inc., Novartis AG, and Takeda Oncology. She has received grant support related to research activities from AbbVie, Agios, Celgene Corporation - A Bristol-Myers Squibb Company, Calithera BioSciences, Inc., Daiichi Sankyo, and Immune-Onc. She has also disclosed a financial relationship with Notable.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.